This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

BeneFIX (nonacog alfa) Prescribing Information for Great Britain click here. BeneFIX (nonacog alfa) Prescribing Information for Northern Ireland click here.
​​​​​​​Adverse event reporting can be found at the bottom of this page.    

​​​​​​​BeneFIX® (nonacog alfa) is recombinant coagulation factor IX indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). BeneFIX® can be used for all age groups.1  

Clinical efficacy​​​​​​​​​​​​​​

​​​​​​​BeneFIX® offers efficacy when you and your patients need it most.2–5    

Prophylactic treatment in PTPs  

of responses were rated as excellent or effective (n=47).2,*   

Prophylactic treatment in PUPs  
​​​​​​​
of responses were rated as excellent† (n=42), indicating that spontaneous musculoskeletal bleeding was prevented.3,​​​​​​​†   

Paediatric patients  

of patients under 6 years old experienced no spontaneous bleeding episodes while on prophylaxis (n=22).5  

*The response to secondary prophylaxis was assessed once every 3 months by the investigator using a 3-point scale: excellent (no spontaneous bleeding of any kind, no change in dosing regimen necessary); effective (no spontaneous musculoskeletal bleeding, no change in dosing regimen necessary); or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).2

​​​​​​​†Rated by the investigator at 3-month intervals on a 3-point scale: excellent (prophylaxis treatment completely prevented spontaneous musculoskeletal bleeding, no change in dosing regimen necessary); effective (adequately prevented spontaneous musculoskeletal bleeding episodes as demonstrated by a lower than expected incidence of spontaneous musculoskeletal bleeding episodes); or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).3  

Prophylaxis

On-demand treatment in PTPs  

of 1,796 bleeding episodes were resolved with only 1 infusion (n=55).2

On-demand treatment PUPs     

of 997 bleeding episodes were resolved with only 1 infusion (n=54).3

Surgery    

of responses were rated excellent or good‡ (n=28).4,§ ,​​​​​​​† ​​​​​​​ 

‡Haemostasis was rated as excellent or good in 34 out of 35 of the operative procedures. Response ratings are defined as follows: excellent if the response was as satisfactory, with as much and as rapid an improvement as the best responses with other factor IX products for similar bleeds or procedures; good if the response was as satisfactory, with as much and as rapid an improvement as most responses with other factor IX products for similar bleeds or procedures; moderate if the response was less than satisfactory and not as good as most responses seen with other factor IX products when used for similar bleeding episodes or similar procedures; or no response if no improvement at all was observed.4  

§29% (8/28) of patients (9 operative procedures) received postoperative BeneFIX® by continuous infusion.4 BeneFIX® is not licensed for use by continuous infusion – please refer to the BeneFIX® Summary of Product Characteristics for further information.1  

On-demand treatment

Explore more

Safety profile

BeneFIX® has well-documented safety profile in both adults and children.1  ​​​​​​​​​​​​​​

Find out more

Contact us

Contact a member of the Pfizer haemophilia team.

Contact us

** This is an optional area where footnotes can live.

BeneFIX® in the real-world setting  

rFIX products like BeneFIX® are effective at preventing bleeds in everyday settings.6  

Find out more

** This is an optional area where footnotes can live.

Abbreviations:  

​​​​​​​PTP, previously treated patients; PUP, previously untreated patients.    
​​​​​​​
References
  1. BeneFIX® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.
  2. Roth DA et al. Blood 2001;98(13):3600–3606.  
  3. Shapiro AD et al. Blood 2005;105(2):518–525.  
  4. Ragni M et al. Haemophilia 2002;8(2):91–97.  
  5. Monahan P et al. Haemophilia 2010;16(3):460–468.  
  6. Chhabra A et al. Blood Coagul Fibrinolysis 2020;31:186–192.  
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
​​​​​​​Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
PP-BEN-GBR-0492. September 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?